Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm

Rhea-AI Summary

Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced that the Brazilian Patent Office granted a notice of allowance for a patent application concerning a method to inhibit biofilm formation, issued on March 31, 2021. This new patent, noted by CEO Robb Knie, is part of the company's strategy to broaden its intellectual property portfolio in underserved global markets. The method, discovered by University of Cincinnati researchers, utilizes a zinc chelator to prevent biofilm creation by bacteria such as Staphylococcus epidermidis and Staphylococcus aureus.

Positive

• Issuance of a patent notice in Brazil, enhancing intellectual property.
• Focus on underserved markets, potentially increasing market opportunities.

Negative

• None.

NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for inhibiting formation of biofilms. The notice of allowance was issued March 31, 2021 and is related to a new patent application not previously announced.

"We are pleased to have been granted this additional patent by the Brazilian government for our novel method for inhibiting the formation of biofilms," said Robb Knie, CEO of Hoth Therapeutics.  "We have continued to expand our intellectual property portfolio related to these global underserved markets, where our novel therapeutics can be applied."

Researchers at the University of Cincinnati discovered that an in vitro method for inhibiting formation of a biofilm comprising bacteria, the method comprising contacting the bacteria with a zinc chelator, wherein the bacteria comprise a zinc adhesion module and wherein the bacteria are selected from the group consisting of Staphylococcus epidermidis and Staphylococcus aureus and combinations thereof, whereby formation of the biofilm is inhibited; characterized in that the zinc chelator comprises DTPA at a concentration of from 20 μM to 2 mM. 

About Hoth Therapeutics

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.

Forward-Looking Statement

This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as 'could,' 'believe,' 'anticipate,' 'intend,' 'estimate,' 'expect,' 'may,' 'continue,' 'predict,' 'potential,' 'project' or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled 'Risk Factors' in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

HOTH THERAPEUTICS INVESTOR RELATIONS CONTACT

Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-inc-announces-notice-of-allowance-for-a-new-patent-application-related-to-a-method-for-inhibiting-formation-of-a-biofilm-301261853.html

SOURCE Hoth Therapeutics, Inc.

FAQ

What is the recent patent announcement from Hoth Therapeutics (HOTH)?

Hoth Therapeutics announced a notice of allowance for a patent related to a method for inhibiting biofilm formation, issued by the Brazilian Patent Office on March 31, 2021.

Who developed the biofilm inhibition method announced by Hoth Therapeutics?

The method for inhibiting biofilm formation was discovered by researchers at the University of Cincinnati.

How does Hoth Therapeutics’ new patent impact its business?

The new patent expands Hoth's intellectual property portfolio, potentially enhancing its competitive edge in underserved global markets.

What type of bacteria does Hoth Therapeutics' biofilm inhibition method target?

The method targets bacteria such as Staphylococcus epidermidis and Staphylococcus aureus.

When was the patent notice for Hoth Therapeutics issued?

The notice of allowance for the patent was issued on March 31, 2021.